Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: Results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole

Archives of Internal Medicine

Volumn 162, Issue 2, 2002, Pages 169-175

  Graham, David Y ^a   Agrawal, Naurang M ^b   Campbell, Donald R ^c,d   Haber, Marian M ^e   Collis, Cyndy ^f   Lukasik, Nancy L ^f   Huang, Bidan ^g  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^g ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GASTROSCOPY; HELICOBACTER PYLORI; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SIDE EFFECT; STOMACH ULCER; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0037185429     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.2.169     Document Type: Article

References (34)

1. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury
2. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs
3. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: Where we stand
4. Prevention of NSAID-induced gastric ulcer with misoprostol: Multicentre, double-blind, placebo-controlled trial
5. Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers: A one-year study
6. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: A randomized, controlled trial
7. Prevention and treatment of ulcers induced by nonsteroidal anti-inflammatory drugs: An update
8. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs
9. Prevention of gastroduodenal injury induced by chronic nonsteroidal antiinflammatory drug therapy
10. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs: Omeprazole versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group
11. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: A prospective, double-blind, multicenter study
12. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: A comparison of three regimens
13. Improving the gastrointestinal safety of NSAIDs: The development of misoprostol - From hypothesis to clinical practice
14. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomized, double-blind, placebo-controlled trial
15. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: Controlled trial of ranitidine
16. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs
17. High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs
18. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs
19. High-dose famotidine for prevention of NSAID ulcers
20. Famotidine to prevent peptic ulcer caused by NSAIDs
21. Famotidine for healing and maintenance in non-steroidal anti-inflammatory drug associated gastro-duodenal ulceration famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration
22. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs
23. A dose ranging study of famotidine in prevention of gastroduodenal lesions associated with nonsteroidal anti-inflammatory drugs (NSAIDs): Results of a U.S. multicenter trial
24. NSAID ulcers: Prevalence and prevention
25. Role of Helicobacter pylori infection in NSAID-associated gastropathy
26. Elimination of Helicobacter pylori under treatment with omeprazole
27. Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety
28. Long-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth, and gastritis
29. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease
30. H2-receptor antagonists and antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients
31. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication
32. Classification and grading of gastritis: The updated Sydney System: International Workshop on the Histopathology of Gastritis, Houston 1994
33. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? a prospective randomized study
34. Ulcer and gastritis